Regulatory Affairs Certification (RAC) Practice Exam 2026 - Free RAC Practice Questions and Study Guide

In the context of planning Phase 2 clinical trials for a novel cancer drug, the focus is primarily on assessing the drug's efficacy and safety in patients who actually have the disease, which in this case are cancer patients. Gathering data from patients with cancer allows researchers to evaluate how well the drug works in the target population and to determine optimal dosing and treatment schedules.

Healthy subjects are not appropriate for Phase 2 trials of cancer drugs because these trials are designed to treat individuals suffering from the specific condition that the drug is intended to address. Employing healthy subjects in this phase would not provide relevant data on the drug's effectiveness or safety profile in the actual patient population. Instead, Trials involving healthy subjects typically occur in Phase 1, where the focus is mainly on safety, tolerability, pharmacokinetics, and pharmacodynamics.

The inclusion of 150 cancer patients, consideration of multiple indications, and evaluation of one or more dose regimens are all essential components of a well-structured Phase 2 trial. These factors contribute to an understanding of how the drug might work across different patient profiles and optimal dosing strategies, which inform subsequent trials and the regulatory submission process.